| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Saoirse E O'Sullivan, Yan Sun, Andrew J Bennett, Michael D Randall, David A Kendal. Time-dependent vascular actions of cannabidiol in the rat aorta. European journal of pharmacology. vol 612. issue 1-3. 2009-07-09. PMID:19285060. |
the vascular effects of cannabidiol were not affected by endothelial denudation, nitric oxide synthase inhibition, pertussis toxin, cannabinoid cb1 or cannabinoid cb2 receptor antagonism, or capsaicin pre-treatment. |
2009-07-09 |
2023-08-12 |
rat |
| Jason R Clapper, Regina A Mangieri, Daniele Piomell. The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology. vol 56 Suppl 1. 2009-04-15. PMID:18691603. |
this signaling system is engaged by the active component of cannabis, delta9-tetrahydrocannabinol (delta9-thc), which exerts its pharmacological effects by activation of g protein-coupled type-1 (cb1) and type-2 (cb2) cannabinoid receptors. |
2009-04-15 |
2023-08-12 |
Not clear |
| G Aviello, B Romano, A A Izz. Cannabinoids and gastrointestinal motility: animal and human studies. European review for medical and pharmacological sciences. vol 12 Suppl 1. 2008-11-14. PMID:18924447. |
delta9-tetrahydrocannabinol, the main psychotropic component of cannabis, acts via at least two types of cannabinoid receptors, named cb1 and cb2 receptors. |
2008-11-14 |
2023-08-12 |
human |
| Barbara L F Kaplan, Alison E B Springs, Norbert E Kaminsk. The profile of immune modulation by cannabidiol (CBD) involves deregulation of nuclear factor of activated T cells (NFAT). Biochemical pharmacology. vol 76. issue 6. 2008-09-29. PMID:18656454. |
cannabidiol (cbd) is a cannabinoid compound derived from cannabis sativa that does not possess high affinity for either the cb1 or cb2 cannabinoid receptors. |
2008-09-29 |
2023-08-12 |
mouse |
| F Teixeira-Clerc, B Julien, P Grenard, J Tran Van Nhieu, V Deveaux, C Hezode, A Mallat, S Lotersztaj. [The endocannabinoid system as a novel target for the treatment of liver fibrosis]. Pathologie-biologie. vol 56. issue 1. 2008-04-18. PMID:17412522. |
in keeping with these results, daily cannabis smoking is a risk factor for fibrosis progression in patients with chronic hepatitis c. in contrast, cb2 display antifibrogenic effects, by a mechanism involving reduction of liver fibrogenic cell accumulation. |
2008-04-18 |
2023-08-12 |
Not clear |
| Atmaram D Khanolkar, Dai Lu, Mohab Ibrahim, Richard I Duclos, Ganesh A Thakur, T Phillip Malan, Frank Porreca, Vijayabaskar Veerappan, Xiaoyu Tian, Clifford George, Damon A Parrish, Demetris P Papahatjis, Alexandros Makriyanni. Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity. Journal of medicinal chemistry. vol 50. issue 26. 2008-04-03. PMID:18038967. |
these novel compounds are structurally related to cannabinol (6,6,9-trimethyl-3-pentyl-6 h-benzo[ c]chromen-1-ol), a natural constituent of cannabis with modest cb2 selectivity. |
2008-04-03 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
the diverse cb1 and cb2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. |
2008-04-02 |
2023-08-12 |
Not clear |
| R G Pertwe. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin. British journal of pharmacology. vol 153. issue 2. 2008-04-02. PMID:17828291. |
delta9-thc, the main psychotropic constituent of cannabis, is a cb1 and cb2 receptor partial agonist and in line with classical pharmacology, the responses it elicits appear to be strongly influenced both by the expression level and signalling efficiency of cannabinoid receptors and by ongoing endogenous cannabinoid release. |
2008-04-02 |
2023-08-12 |
Not clear |
| Estera Páldyová, E Bereczki, M Sántha, T Wenger, Anna Borsodi, S Benyh. Altered gene expression and functional activity of opioid receptors in the cerebellum of CB1 cannabinoid receptor knockout mice after acute treatments with cannabinoids. Acta biologica Hungarica. vol 58 Suppl. 2008-04-02. PMID:18297798. |
the goal of this study was to evaluate whether acute treatments by endogenous cannabinoid agonist, selective cb1 or cb2 receptor antagonists modulate the expression of mu- (mor) and delta- (dor) opioid receptor mrna levels and functional activity in the cerebellum of transgenic mice deficient in the cb1 type of cannabis receptors. |
2008-04-02 |
2023-08-12 |
mouse |
| C R Hiley, S S Kau. GPR55 and the vascular receptors for cannabinoids. British journal of pharmacology. vol 152. issue 5. 2008-02-25. PMID:17704825. |
cb1 and cb2 receptors mediate most responses to cannabinoids but not some of the cardiovascular actions of endocannabinoids such as anandamide and virodhamine, or those of some synthetic agents, like abnormal cannabidiol (abn-cbd). |
2008-02-25 |
2023-08-12 |
mouse |
| R G Pertwe. GPR55: a new member of the cannabinoid receptor clan? British journal of pharmacology. vol 152. issue 7. 2008-02-05. PMID:17876300. |
for example, the cb1 receptor antagonist, am251, activated gpr55 and the main psychoactive constituent of cannabis, delta9-tetrahydrocannabinol, displayed greater efficacy at gpr55 than at cb1 or cb2 receptors. |
2008-02-05 |
2023-08-12 |
mouse |
| Onintza Sagredo, José A Ramos, Alessandra Decio, Raphael Mechoulam, Javier Fernández-Rui. Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. The European journal of neuroscience. vol 26. issue 4. 2007-10-25. PMID:17672854. |
we used the cb1 agonist arachidonyl-2-chloroethylamide (acea), the cb2 agonist hu-308, and cannabidiol (cbd), an antioxidant phytocannabinoid with negligible affinity for cannabinoid receptors. |
2007-10-25 |
2023-08-12 |
rat |
| Christian C Felder, Amy K Dickason-Chesterfield, Steven A Moor. Cannabinoids biology: the search for new therapeutic targets. Molecular interventions. vol 6. issue 3. 2007-06-22. PMID:16809476. |
the discovery of tetrahydrocannabinol, the active principal in marijuana, and the identification and cloning of two cannabinoid receptors (i.e., cb1 and cb2) has subsequently led to biomedical appreciation for a family of endocannabinoid lipid transmitters. |
2007-06-22 |
2023-08-12 |
Not clear |
| Emmanuel S Onaiv. Neuropsychobiological evidence for the functional presence and expression of cannabinoid CB2 receptors in the brain. Neuropsychobiology. vol 54. issue 4. 2007-06-13. PMID:17356307. |
for over a decade, until recently, it was thought that marijuana acts by activating brain-type cannabinoid receptors called cb1, and that a second type called cb2 cannabinoid receptor was found only in peripheral tissues. |
2007-06-13 |
2023-08-12 |
mouse |
| A Thomas, G L Baillie, A M Phillips, R K Razdan, R A Ross, R G Pertwe. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British journal of pharmacology. vol 150. issue 5. 2007-05-10. PMID:17245363. |
cannabidiol displays unexpectedly high potency as an antagonist of cb1 and cb2 receptor agonists in vitro. |
2007-05-10 |
2023-08-12 |
mouse |
| A Thomas, G L Baillie, A M Phillips, R K Razdan, R A Ross, R G Pertwe. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British journal of pharmacology. vol 150. issue 5. 2007-05-10. PMID:17245363. |
a nonpsychoactive constituent of the cannabis plant, cannabidiol has been demonstrated to have low affinity for both cannabinoid cb1 and cb2 receptors. |
2007-05-10 |
2023-08-12 |
mouse |
| A Thomas, G L Baillie, A M Phillips, R K Razdan, R A Ross, R G Pertwe. Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro. British journal of pharmacology. vol 150. issue 5. 2007-05-10. PMID:17245363. |
this study aimed to investigate whether these properties of cannabidiol extend to cb1 receptors expressed in mouse brain and to human cb2 receptors that have been transfected into cho cells. |
2007-05-10 |
2023-08-12 |
mouse |
| Robert J McKallip, Wentao Jia, Jerome Schlomer, James W Warren, Prakash S Nagarkatti, Mitzi Nagarkatt. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Molecular pharmacology. vol 70. issue 3. 2006-09-28. PMID:16754784. |
exposure of leukemia cells to cannabidiol led to cannabinoid receptor 2 (cb2)-mediated reduction in cell viability and induction in apoptosis. |
2006-09-28 |
2023-08-12 |
human |
| Robert J McKallip, Wentao Jia, Jerome Schlomer, James W Warren, Prakash S Nagarkatti, Mitzi Nagarkatt. Cannabidiol-induced apoptosis in human leukemia cells: A novel role of cannabidiol in the regulation of p22phox and Nox4 expression. Molecular pharmacology. vol 70. issue 3. 2006-09-28. PMID:16754784. |
together, the results from this study reveal that cannabidiol, acting through cb2 and regulation of nox4 and p22(phox) expression, may be a novel and highly selective treatment for leukemia. |
2006-09-28 |
2023-08-12 |
human |
| Ken Mackie, Nephi Stell. Cannabinoid receptors and endocannabinoids: evidence for new players. The AAPS journal. vol 8. issue 2. 2006-08-11. PMID:16796380. |
it is now well established that the psychoactive effects of cannabis sativa are primarily mediated through neuronal cb1 receptors, while its therapeutic immune properties are primarily mediated through cb2 receptors. |
2006-08-11 |
2023-08-12 |
Not clear |